Dietary celecoxib improves DC-based immunotherapy. Mice were inoculated i.p. with 0.5 × 106 AB1 tumour cells at day 0. A suboptimal DC-treatment protocol was used. Mice were treated with DC-based immunotherapy at day 10 after tumour injection. Mice received control diet or celecoxib diet from day 1 onwards. All groups consisted of 6 mice. Survival was measured using Kaplan-Meier survival analysis. Combining DC-based immunotherapy with dietary celecoxib improved survival (p = 0.027), compared to a single treatment with celecoxib (p = 0.305) or DC-based immunotherapy (p = 0.456). All compared to no treatment.